Drug Detail:Lasmiditan (Lasmiditan)
Drug Class: Antimigraine agents
Usual Adult Dose for Migraine
Initial dose: 50 mg, 100 mg, or 200 mg orally once
Maximum dose: 1 dose per day
Comments:
- This drug should not be taken unless the patient can wait 8 hours or more before driving or operating machinery.
- No more than 1 dose should be taken in 24 hours; a second dose has not been shown to be effective for the same migraine attack.
- The safety of treating an average of more than 4 migraine attacks in a 30-day period has not been established.
- This drug is not indicated for the prevention of migraine attacks.
Use: For the acute treatment of migraine with or without aura.
Renal Dose Adjustments
No adjustment recommended
Liver Dose Adjustments
Mild to moderate hepatic impairment: No adjustment recommended
Severe hepatic impairment: Not recommended
Dose Adjustments
Elderly: Dose selection should be cautious, generally starting at the low end of the dosing range
Precautions
CONTRAINDICATIONS:
- None
Safety and efficacy have not been established in patients younger than 18 years.
Consult WARNINGS section for additional precautions.
US Controlled Substance: Schedule V
Dialysis
Data not available
Other Comments
Administration advice:
- Take orally with or without food; swallow tablets whole, do not split, crush, or chew
- Do not take more than 1 dose in a 24 hour period; the safety of treating an average of more than 4 migraine attacks in a 30-day period has not been established
- Patients should wait at least 8 hours after dosing before driving or operating machinery
General:
- In a human abuse potential study, this drug showed statistically significantly higher "drug liking" scores than placebo and statistically significantly lower scores compared to alprazolam 2 mg; euphoric mood occurred to a similar extent with lasmiditan doses of 200 mg and 400 mg and alprazolam 2 mg (43% to 49%).
- Concomitant use with other CNS depressant drugs has not been evaluated in clinical studies.
- Patients should understand that they may not be able to assess their own driving competence and the degree of impairment caused by this drug; if they are unable to wait 8 hours or more before driving a motor vehicle or operating machinery, they should not take this medication.
Monitoring:
- Monitor for risk of drug abuse and signs of misuse or abuse
- Monitor heart rate in patients for whom changes in heart rate may be problematic
- Monitor blood pressure in patients for whom increased blood pressure not be tolerated
Patient advice:
- Patients should be instructed to read the US FDA-approved patient labeling (Patient Information and Instructions for Use).
- Patients should be instructed to avoid driving or operating machinery for at least 8 hours after taking a dose; if they are not able to wait the necessary time, they should not take a dose.
Frequently asked questions
- What are the new drugs for the treatment of migraines?
